Epizyme says it’s excited by PhII data, but there’s plenty to fret about
Epizyme execs spent most of the day on Sunday making the case that their lead cancer drug tazemetostat just cleared an important milestone at an …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
